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INTRODUCTION
Patients with BRCA1/2-associated EOCs exhibit improved overall survival and high sensitivity to double strand DNA break inducing agents due to an underlying defect in DNA repair via HR.
However, it is increasingly recognized that a subset of patients with sporadic EOCs also exhibit defective HR caused by mechanisms that are unrelated to germline BRCA1 or BRCA2
mutations. These tumors may behave similarly to BRCA1/2-mutated EOCs and are commonly referred to as having a "BRCAness" phenotype (i.e. BRCAlike). Identifying tumors with a BRCAness phenotype is of increased clinical importance not only due to the advent of PARPinhibitors but also because patients with this phenotype may need to be managed differently than the remaining patients. We have developed a 60-gene expression profile that may identify tumors with a BRCAness phenotype and may also be used to identify compounds that can enhance responsiveness to platinum and PARP-inhibitors. In this annual progress report of the work performed from 7/15/2014 to 7/14/2015, we:
i) present data on a unique subset of ovarian cancers which are not BRCAlike, i.e. not HR deficient and thus are resistant to PARPis but are sensitive to platinum.
ii) present data that HSP90-inhibitors which were identified via our BRCAness profile may sensitize PARPi resistant xenograft models to PARPis.
iii) update our progress on validating our profile in a cohort of molecularly defined BRCAmutated and HR-proficient tumors.
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ACCOMPLISHMENTS
o What were the major goals of the project?
The major goals of this project during this period were to continue our work along Tasks 1, 3 and 4. The first goal was to identify subsets of ovarian cancers which are BRCAlike or nonBRCAlike and to further characterize their sensitivity to platinum and PARPi (Task 1).
Another goal was to provide further data showing that HSP90-inhibitors sensitize ovarian cancers to PARPis (Task 3). Finally, in our Task 4, our goal was to continue working towards validating our profile in a cohort of molecularly defined BRCA-mutated and HR-proficient tumors.
o
What was accomplished under these goals?
We have fully accomplished the goals of this project during this period.
Task 1.
Determine whether the BRCAness gene expression profile is capable of prospectively identifying sporadic patients whose tumors exhibit defects in homologous recombination and increased sensitivity to platinum and PARP inhibitors in vitro.
In addition and in continuation of the work we have performed the previous years, we were able to define a unique subset of ovarian cancers which are not BRCAlike, i.e. not HR deficient and thus are resistant to PARPis but are sensitive to platinum. Specifically, we curated the EOC TCGA dataset to assess potential inactivating events of the nucleotide excision repair (NER) pathway including mutations, homozygous deletions and promoter hypermethylation of NER genes. We found that a total of 24 (8%) of 316 EOCs harbored either NER mutations or homozygous deletions of NER genes (Fig. 1A) . Specifically, we identified 19 cases with nonsynonymous or splice site NER gene mutations (all somatic) and 6 cases with homozygous deletions of NER genes among the 316 sequenced EOCs of the TCGA dataset. None of the NER genes were found to harbor promoter hypermethylation. All NER mutations were mutually exclusive, i.e. no individual tumor harbored mutations in more than one NER gene. Furthermore, NER mutations were mutually exclusive with homozygous deletions of the NER genes with the exception of one case that harbored both an ERCC5 mutation and homozygous deletion of As a proof of principle that NER alterations are functionally associated with platinum sensitivity, we evaluated one NER mutation (ERCC6-Q524*) that was present in a patient with stage IV suboptimally-debulked high grade serous tumor that had complete response to first line platinum chemotherapy and remained in complete remission for 31.5 months after diagnosis. In order to determine the functional significance of ERCC6-Q524* on platinum sensitivity, we evaluated whether this variant could rescue platinum sensitivity in an ERCC6-deficient cell line.
An ERCC6-deficient immortalized fibroblast cell line (GM16095) was complemented with either wild-type ERCC6 or the mutant ERCC6-Q524*. Expression of wild-type ERCC6 rescued cisplatin sensitivity of ERCC6-deficient cells while complementation with mutant ERCC6-Q524* did not impact cisplatin sensitivity ( Fig. 2A) . In order to confirm that ERCC6 loss alone is solely sufficient to induce cisplatin sensitivity, we assessed cisplatin cytotoxicity following siRNA knockdown of ERCC6. ERCC6 depletion significantly increased platinum sensitivity, comparable to BRCA2 loss, a major mediator of DNA crosslink repair.
Given that ERCC6-Q524* was a somatic mutation and not associated with heterozygous loss,
we evaluated whether this mutation may exert a dominant negative effect. We postulated that ERCC6-Q524* may interfere with the function of the wild-type allele and hence increase sensitivity to cisplatin. Indeed, introduction of the ERCC6-Q524* variant in ERCC6 wild-type 293T cells dramatically increased cisplatin sensitivity compared to cells transfected either with wild-type ERCC6 or control empty vector suggesting that this mutation sensitizes cells to cisplatin by a dominant negative mechanism (Fig. 2B ).
Figure 2.
We evaluated the association of this NER mutation with sensitivity to the PARPi rucaparib. In conclusion, we report for the first time that NER pathway alterations (mutations and homozygous deletions) occur in EOC and that these alterations are associated with a phenotype of clinical platinum sensitivity that is similar to that of BRCA1/2-mutated tumors characterized by improved overall and progression free survival. We showed that the NER mutation identified in a very platinum sensitive tumor (ERCC6-Q524*) was functionally associated with platinum sensitivity in vitro. Importantly, this mutation did not affect HR and did not confer sensitivity to
PARPi thus providing a novel mechanism of discordance between platinum and PARPi sensitivity in EOC. Our findings suggest that NER alterations may have a previously This task has already been completed.
Task 3. Evaluate whether the compounds identified by the Connectivity Map can reverse PARP
resistance in vitro, and to investigate the mechanism for this effect.
In addition to the in vitro data, we have now performed experiments to assess whether HSP90 inhibitors identified via the Connectivity Map can revert PARPi resistance in vivo.
Specifically, we used a PARPi resistant xenograft model and we performed efficacy studies. Strikingly, this model was PARPi resistant and was also resistant to combinations of olaparib and the PI3K inhibitors BKM120 or BYL719.
Olaparib was dosed at 100mg/kg po daily x 4 weeks, AT13387 (HSP90i) was administered at 45mg/kg po for 2 days (D1,D2) on / 5 days off x 4 weeks (i.e. Days 1, 2, 8, 9, 15, 16, 22, 23).
As shown in Figure 3 , the combination of AT13387 and olaparib induced inhibition of tumor growth as opposed to vehicle control, olaparib alone and AT13387 alone. A very important step towards assessing the reproducibility of our BRCAness profile is to identify the right cohort of molecularly defined patients that are BRCAlike and nonBRCAlike. To achieve this, we defined two groups of patients, a BRCA1/2-mutated group which is expected to be BRCAlike and a HR-proficient group which is expected to be nonBRCAlike.
The BRCA1/2-mutated group was comprised of 37 HGSOCs (29 with BRCA1 and 8 with BRCA2 mutations) with BRCA1/2 germline mutations identified by genetic testing (Figure 2 ). The HRproficient group (i.e. group of tumors without HR alterations) comprised 16 ovarian cancers which were identified in a two-step process (Figure 2 ). First, we performed Next Generation Nothing to report. 
CHANGES/PROBLEMS

What other organizations were involved as partners?
Nothing to report.
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